Home
Statistics
Acknowledgment
Enquire
Keyword Search
Complex Search
Segment Search
Peptide Mapping
Browse On
Mode of delivery
Animal model
Origin/Source
Peptide Length
Similarity
BLAST Search
Smith-Waterman
General
Help or Guide
Data Submission
Curators
Developers
Contact Us
Browse result page of B3Pdb
The total number entries retrieved from this search are
235
, scroll left/right for detailed information.
B3pdbID
PEPTIDE NAME
PEPTIDE SEQUENCE (1-letter)
PEPTIDE SEQUENCE (3-letter)
N-TERMINAL MODIFICATION
C-TERMINAL MODIFICATION
CHEMICAL MODIFICATION
PEPTIDE LENGTH
PEPTIDE CONFORMATION
PEPTIDE NATURE
SOURCE/ORIGIN OF PEPTIDE
SMILES
CELL LINE
In vitro
CONCENTRATION
In vitro
METHOD
In vitro
RESULT
ANIMAL MODEL
In vivo
CONCENTRATION
In vivo
MODE OF DELIVERY
In vivo
METHOD
In vivo
RESULT
ACTION
TRANSPORT TYPE
SUBCELLULAR LOCALISATION
COMBINATION
PHYSICAL CONDITION
RESPONSE
RESULT
LABEL
PMID
b3pdb_1138
Neuromedin B
GNLWATGHFM
Gly-Asn-Leu-Trp-Ala-Thr-Gly-His-Phe-Met-NH2
NA
NA
NA
10
Linear
NA
human
NA
NA
NA
NA
NA
NA
NA
Intravenous
NA
NA
NA
Permeability
NA
NA
NA
Initial disrobution volume
0.00799 ml/g
Direct iodination
27040796
b3pdb_1139
Arginine vasopressin
CYFQNCP
Cys-Tyr-Phe-Gln-Asn-Cys-Pro
NA
NA
Cys1-Cys6
7
Linear
NA
human
N[C@@]([H])(CS)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)N[C@@]([H])(CCC(=O)N)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CS)C(=O)N1[C@@]([H])(CCC1)C(=O)O
NA
NA
Initial concentration in donor chamber-Culture
NA
NA
NA
NA
NA
NA
NA
non saturable
NA
NA
NA
Permeability index
46 (x 10-4) cm/min
NA
2732952
b3pdb_1140
Arginine vasopressin
CYFQNC
Cys-Tyr-Phe-Gln-Asn-Cys
NA
NA
Cys1-Cys6
6
Linear
NA
human
N[C@@]([H])(CS)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)N[C@@]([H])(CCC(=O)N)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CS)C(=O)O
NA
NA
Initial concentration in donor chamber-Culture
NA
NA
NA
NA
NA
NA
NA
Permeability
NA
NA
NA
Permeability index
30 (x 10-4) cm/min
NA
2732952
b3pdb_1141
[Ser7-O-βGlc]dermorp
YaFGYPS-NH2
Tyr-(D)Ala-Phe-Gly-Tyr-Pro-Ser-NH2
NA
NA
NA
7
Linear
NA
human
NA
NA
NA
anti-nociception
NA
NA
NA
NA
NA
NA
NA
Permeability
NA
NA
NA
ICV/SC ratio
0.0000195
NA
9723966
b3pdb_1142
[Ser7-O-βGlc(Ac)4]de
YaFGYPS-NH2
Tyr-(D)Ala-Phe-Gly-Tyr-Pro-Ser-NH2
NA
NA
NA
7
Linear
NA
human
NA
NA
NA
anti-nociception
NA
NA
NA
NA
NA
NA
NA
Permeability
NA
NA
NA
ICV/SC ratio
0.0000098
NA
9723966
b3pdb_1143
[Ala7-C-αGal]dermorp
YaFGYPS-NH2
Tyr-(D)Ala-Phe-Gly-Tyr-Pro-Ser-NH2
NA
NA
NA
7
Linear
NA
Chemically synthesized
NA
NA
NA
anti-nociception
NA
NA
NA
NA
NA
NA
NA
Permeability
NA
NA
NA
ICV/SC ratio
0.0000334
NA
9723966
b3pdb_1144
[Ala7-C-αGal(Ac)4]de
YaFGYPS-NH2
NA
NA
NA
NA
7
Linear
NA
Chemically synthesized
NA
NA
NA
anti-nociception
NA
NA
NA
NA
NA
NA
NA
Permeability
NA
NA
NA
ICV/SC ratio
0.0000089
NA
NA
b3pdb_1150
Beauvericin
NA
NA
NA
NA
NA
6
Linear
NA
Chemically synthesized
NA
NA
NA
Efflux study ICU
NA
NA
NA
NA
NA
NA
NA
Permeability
NA
NA
NA
Brain elemination rate constant
-0.1205 min-1
Direct iodination
27349679
b3pdb_1151
Beauvericin
NA
NA
NA
NA
NA
6
Linear
NA
Chemically synthesized
NA
NA
NA
Capillary depletion
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
% parenchyma
91.92%
Direct iodination
27349679
b3pdb_1152
Beauvericin
NA
NA
NA
NA
NA
6
Linear
NA
Chemically synthesized
NA
NA
NA
Capillary depletion
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
% parenchyma
8.08%
Direct iodination
27349679
b3pdb_1153
Beauvericin
NA
NA
NA
NA
NA
6
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
Intravenous
NA
NA
NA
Permeability
NA
NA
NA
Unidirectional influx rate constant
0.01115 mL/(g x min)
Direct iodination
27349679
b3pdb_1154
Beauvericin
NA
NA
NA
NA
NA
6
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
Intravenous
NA
NA
NA
Permeability
NA
NA
NA
Initial disrobution volume
0.02191 ml/g
Direct iodination
27349679
b3pdb_1155
PepH1
VQQLTKRFSL
ValGlnGlnLeuThrLysArgPheSerLeu
NA
NA
NA
10
Linear
NA
Chemically synthesized
N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCC(=O)N)C(=O)N[C@@]([H])(CCC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
NA
NA
Initial concentration in donor chamber-Culture
NA
NA
NA
NA
NA
NA
NA
Permeability
NA
NA
NA
Translocated
73.83%
99mTc(CO)3+
28263555
b3pdb_1156
PepH1
VQQLTKRFSL
ValGlnGlnLeuThrLysArgPheSerLeu
NA
NA
NA
10
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
Intravenous
NA
NA
NA
Permeability
NA
NA
NA
% injected dose
0.02 %/g
99mTc(CO)3+
28263555
b3pdb_1158
PepH3
AGILKRW
AlaGlyIleLeuLysArgTrp
NA
NA
NA
7
Linear
NA
viral
NA
NA
NA
Initial concentration in donor chamber-Culture
NA
NA
NA
NA
NA
NA
NA
Permeability
NA
NA
NA
Translocated
67.23%
99mTc(CO)3+
28263555
b3pdb_1159
PepH3
AGILKRW
AlaGlyIleLeuLysArgTrp
NA
NA
NA
7
Linear
NA
viral
NA
NA
NA
NA
NA
NA
NA
Intravenous
NA
NA
NA
Permeability
NA
NA
NA
% injected dose
0.03 %/g
99mTc(CO)3+
28263555
b3pdb_1168
PepNeg
SGTQEEY
Ser-Gly-Thr-Gln-Glu-Glu-Tyr
NA
NA
NA
7
Linear
NA
Chemically synthesized
NA
NA
NA
Initial concentration in donor chamber-Culture
NA
NA
NA
NA
NA
NA
NA
Permeability
NA
NA
NA
Translocated
42.50%
NA
29057814
b3pdb_1171
LLVV-H4
LLVVYPWT
Leu-Leu-Val-Val-Tyr-Pro-Trp-Thr
NA
NA
NA
8
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
b3pdb_1172
LVV-H4
LVVYPWT
Leu-Val-Val-Tyr-Pro-Trp-Thr
NA
NA
NA
7
Linear
NA
Chemically synthesized
NA
NA
NA
Initial concentration in donor chamber-Culture
NA
NA
NA
NA
NA
NA
NA
Permeability
NA
NA
NA
Area
3.2 Counts
NA
29692758
b3pdb_1173
VV-H4
VVYPWT
Val-Val-Tyr-Pro-Trp-Thr
NA
NA
NA
6
Linear
NA
Hemoglobin
NA
NA
NA
Initial concentration in donor chamber-Culture
NA
NA
NA
NA
NA
NA
NA
Permeability
NA
NA
NA
Area
4 Counts
NA
29692758
b3pdb_1174
VV-H7
VVYPWTQRF
Val-Val-Tyr-Pro-Trp-Thr-Gln-Arg-Phe
NA
NA
NA
8
Linear
NA
Hemoglobin
NA
NA
NA
Initial concentration in donor chamber-Culture
NA
NA
NA
NA
NA
NA
NA
Permeability
NA
NA
NA
Area
4.4 Counts
NA
29692758
b3pdb_1175
H7
YPWTQRF
Tyr-Pro-Trp-Thr-Gln-Arg-Phe
NA
NA
NA
7
Linear
NA
Hemoglobin
NA
NA
NA
Initial concentration in donor chamber-Culture
NA
NA
NA
NA
NA
NA
NA
Permeability
NA
NA
NA
Area
1 Counts
NA
29692758
b3pdb_1188
NT2
Cav-RPYIL
Cav-Arg-Pro-Tyr-Ile-Leu
NA
NA
NA
6
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
PAMPA
NA
NA
NA
Permeability
NA
NA
NA
Translocated
85%
NA
30374780
b3pdb_1189
NT4
R-Cav-PYIL
Arg-Cav-Pro-Tyr-Ile-Leu
NA
NA
NA
6
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
PAMPA
NA
NA
NA
Permeability
NA
NA
NA
Translocated
90%
NA
30374780
b3pdb_1205
OP5
NFDVLTEQ
Asn - Phe - Asp - Val - Leu - Thr - Glu - Gln
NA
NA
NA
8
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
Intravenous
NA
NA
NA
Permeability
NA
NA
NA
Unidirectional influx rate constant
0.0396 ml/g
H3/C14
29966196
b3pdb_1206
SLSHSPQ
SLSHSPQ
Ser - Leu - Ser - His - Ser - Pro - Gln
NA
NA
NA
7
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
b3pdb_1207
NTGSPYE
NTGSPYE
Asn - Thr - Gly - Ser - Pro - Tyr - Glu
NA
NA
NA
7
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
b3pdb_1211
P15
VQITYK
NA
N-terminal acetylation
C-terminal amidation
NA
6
Linear
NA
Chemically synthesized
NA
Human brain endothelial cells (EA.hy926)
NA
Field-emission transmission electron microscope
A3 peptide treated with this peptide, showed higher folds of decrease in fluorescence intensities a
NA
NA
NA
NA
NA
Trojan peptides are capable of translo- cating the BBB, without affecting its interity.
Translocation
NA
Comined with A3 pepide
Tauopathies
These peptides were capable of reducing the tau elicit toxicity by accelerating or impeding the self
These peptide-based modulators (Trojans) were non-amyloidogenic, stable in serum and showed minimal
NA
32114026
b3pdb_1212
P16
VQILYK
NA
N-terminal acetylation
C-terminal amidation
NA
6
Linear
NA
Chemically synthesized
NA
Human brain endothelial cells (EA.hy926)
NA
Field-emission transmission electron microscope
A3 peptide treated with this peptide, showed higher folds of decrease in fluorescence intensities a
NA
NA
NA
NA
NA
Trojan peptides are capable of translo- cating the BBB, without affecting its interity.
Translocation
NA
Comined with A3 pepide
Tauopathies
These peptides were capable of reducing the tau elicit toxicity by accelerating or impeding the self
These peptide-based modulators (Trojans) were non-amyloidogenic, stable in serum and showed minimal
NA
32114026
b3pdb_1213
P17
VQIIYK
NA
N-terminal acetylation
C-terminal amidation
NA
6
Linear
NA
Chemically synthesized
NA
Human brain endothelial cells (EA.hy926)
NA
Field-emission transmission electron microscope
A3 peptide treated with this peptide, showed higher folds of decrease in fluorescence intensities a
NA
NA
NA
NA
NA
Trojan peptides are capable of translo- cating the BBB, without affecting its interity.
Translocation
NA
Comined with A3 pepide
Tauopathies
These peptides were capable of reducing the tau elicit toxicity by accelerating or impeding the self
These peptide-based modulators (Trojans) were non-amyloidogenic, stable in serum and showed minimal
NA
32114026
b3pdb_1214
P18
VQIVYK
NA
NA
C-terminal amidation
NA
6
Linear
NA
Chemically synthesized
NA
Human brain endothelial cells (EA.hy926)
NA
Field-emission transmission electron microscope
A3 peptide treated with this peptide, showed higher folds of decrease in fluorescence intensities a
NA
NA
NA
NA
NA
Trojan peptides are capable of translo- cating the BBB, without affecting its interity.
Translocation
NA
Comined with A3 pepide
Tauopathies
These peptides were capable of reducing the tau elicit toxicity by accelerating or impeding the self
These peptide-based modulators (Trojans) were non-amyloidogenic, stable in serum and showed minimal
NA
32114026
b3pdb_1215
P19
VQILYK
NA
NA
C-terminal amidation
NA
6
Linear
NA
Chemically synthesized
NA
Human brain endothelial cells (EA.hy926)
NA
Field-emission transmission electron microscope
A3 peptide treated with this peptide, showed higher folds of decrease in fluorescence intensities a
NA
NA
NA
NA
NA
Trojan peptides are capable of translo- cating the BBB, without affecting its interity.
Translocation
NA
Comined with A3 pepide
Tauopathies
These peptides were capable of reducing the tau elicit toxicity by accelerating or impeding the self
These peptide-based modulators (Trojans) were non-amyloidogenic, stable in serum and showed minimal
NA
32114026
b3pdb_1216
P20
VQIYK
NA
NA
C-terminal amidation
NA
6
Linear
NA
Chemically synthesized
NA
Human brain endothelial cells (EA.hy926)
NA
Field-emission transmission electron microscope
A3 peptide treated with this peptide, showed higher folds of decrease in fluorescence intensities a
NA
NA
NA
NA
NA
Trojan peptides are capable of translo- cating the BBB, without affecting its interity.
Translocation
NA
Comined with A3 pepide
Tauopathies
These peptides were capable of reducing the tau elicit toxicity by accelerating or impeding the self
These peptide-based modulators (Trojans) were non-amyloidogenic, stable in serum and showed minimal
NA
32114026
b3pdb_1217
P21
VQIVYK
NA
NA
C-terminal amidation
NA
6
Linear
NA
Chemically synthesized
NA
Human brain endothelial cells (EA.hy926)
NA
Field-emission transmission electron microscope
A3 peptide treated with this peptide, showed higher folds of decrease in fluorescence intensities a
NA
NA
NA
NA
NA
Trojan peptides are capable of translo- cating the BBB, without affecting its interity.
Translocation
NA
Comined with A3 pepide
Tauopathies
These peptides were capable of reducing the tau elicit toxicity by accelerating or impeding the self
These peptide-based modulators (Trojans) were non-amyloidogenic, stable in serum and showed minimal
NA
32114026
b3pdb_1222
AP9
NPNDKYEPF
NA
NA
C-terminal amidation
NA
9
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
Mice
20 mg/kg
Intravenous
Evans blue dye
The preservation of the protective effect of double AP9 administration in the postischemic period.
It induce β-arrestin-2-dependent cytoprotective pathways.
NA
NA
Alone
Photothrombosis - induced ischemia
NA
NA
NA
32547356
previous
1
2
3
4
5
next
IIITD/CB
Raghava's Group
IMTECH
CellPPDMOD